Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab
During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.
Authors
- Martín Rudwaleit (ORCID: https://orcid.org/0000-0001-5445-548X)
- Frank Behrens (ORCID: https://orcid.org/0000-0001-8750-7186)
- Jan Brandt‐Jürgens
- Christopher T. Ritchlin (ORCID: https://orcid.org/0000-0002-2602-1219)
- Daniel Peterlik
- Erhard Quebe‐Fehling (ORCID: https://orcid.org/0000-0003-1507-9543)
- Atul A. Deodhar (ORCID: https://orcid.org/0000-0002-2130-1246)
Institutions
- Goethe University Frankfurt (DE)
- Novartis (Switzerland) (CH)
- Oregon Health & Science University (US)
- University of Rochester Medical Center (US)
- Novartis (Germany) (DE)
- Klinikum Bielefeld (DE)
- Fraunhofer Institute for Molecular Biology and Applied Ecology (DE)
Publication Details
- Journal
- Therapeutic Advances in Musculoskeletal Disease
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1177/1759720x251340255
- Citations
- 2
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 3.41